The use of Fentiazac, a nonsteroid anti-inflammatory agent endowed with a high prostaglandin-inhibiting activity, demonstrated a highly significant therapeutic activity in a controlled trial, carried out versus placebo, on 40 patients affected with essential dysmenorrhea.
|Translated title of the contribution||Controlled trial with a prostaglandin-inhibiting non-steroid anti-inflammatory agent in essential dysmenorrhea|
|Number of pages||6|
|Publication status||Published - 1982|
ASJC Scopus subject areas
- Obstetrics and Gynaecology